^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TetMYB

    i
    Other names: TetMYB, TetMYB Vaccine, DNA vaccine TetMYB, DNA-based TetMYB vaccine
    Associations

    News

    Trials
    Company:
    Peter MacCallum Cancer Centre
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    almost2years
    MYPHISMO: MYB and PD-1 Immunotherapies Against Multiple Oncologies Trial (clinicaltrials.gov)
    P1, N=27, Active, not recruiting, Peter MacCallum Cancer Centre, Australia | Not yet recruiting --> Active, not recruiting | Trial primary completion date: Dec 2019 --> Dec 2022
    Enrollment closed • Trial primary completion date
    |
    IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    Tevimbra (tislelizumab) • TetMYB